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Response to HeR2 Inhibition in a 
patient With Brain Metastasis With 
eGFR tKI acquired Resistance and 
an HeR2 amplification
Arenda D. Meedendorp, Arja ter Elst, Nils A. ’t Hart, Harry J. M. Groen,  
Ed Schuuring and Anthonie J. van der Wekken*
University of Groningen and University Medical Center Groningen, Groningen, Netherlands
A 62-year-old man was referred to our university hospital for treatment of advanced 
adenocarcinoma of the lung after disease progression on two lines of EGFR TKI and one 
line of chemotherapy. Fluorescent in situ hybridization analysis upon progression showed 
an HER2 amplification. At our weekly Molecular Tumor Board (MTB), a decision was 
made to treat this patient with afatinib, which resulted in a partial response. However, 
progression was observed with a facial nerve paresis due to a metastasis in the skull. 
A biopsy of a location in the thorax revealed the presence of an EGFR-T790M mutation 
associated with acquired resistance, after which treatment with osimertinib was started. 
After 6 months, disease progression was observed, and a new biopsy was taken from 
the pelvic bone, which revealed the original amplification of HER2 together with the 
EGFR-L858R mutation, the EGFR-T790M mutation was not detected. The MTB decided 
to treat the patient with trastuzumab/paclitaxel. A partial response was observed in dif-
ferent bone lesions, while the skull metastasis with ingrowth in the brain remained stable 
for 6 months. Because of progression of the bone metastases after 6 months, a biopsy 
of a lesion in the thorax wall was taken. In this lesion, the EGFR-T790M mutation could 
be detected again. The MTB advised to start treatment with a combination of osimertinib 
and afatinib. This resulted in an impressive clinical improvement and a partial response 
of the bone metastases on the most recent 18-fluorodeoxyglucose positron emission 
tomography and computer tomography-scan. In conclusion, adjusting treatment to the 
mutational make-up of the tumor is a great challenge. For optimal treatment response 
multiple biopsies and re-biopsy upon progression are imperative. As more genes are 
investigated, treatment decision becomes increasingly difficult, therefore, expert opin-
ions from an MTB is essential.
Keywords: eGFR, HeR2, non-small-cell lung carcinoma, tKI, brain metastasis, Molecular tumor Board
INtRoDUCtIoN
Treatment of driver mutations cannot be based on large clinical trials or high levels of evidence at all 
times. However, a Molecular Tumor Board (MTB) can help in making treatment decisions based on 
databases, case reports, xenograft models, and cell lines. Here, we present such a case.
FIGURe 1 | Computed tomography images showing the thoracic wall lesions of the adenocarcinoma of the lung and MRI images showing the metastasis in the 
skull with ingrowth in the brain at different time points in combination with treatment started at those time points. Abbreviation: PD, progressive disease. White 
circles indicate lesion, which showed progression.
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A 62-year-old man was referred to our university hospital for 
treatment of advanced adenocarcinoma of the lung after disease 
progression on two lines of EGFR TKI and one line of chemo-
therapy in September 2015 (Figure 1).
Four months prior, in April 2015, he was diagnosed with an 
adenocarcinoma of the left lung with multiple bone metastases 
in sternum, ribs, and vertebrae. A biopsy from a metastasis in 
the left femur showed a mutation in the EGFR gene: c.2573T>G; 
p.(L858R). He was initially treated with gefitinib. After 2 months, 
the patient showed progression of bone metastases; the same 
EGFR mutation was found in a biopsy of a rib metastasis, without 
additional mutations in other mutational hotspots (e.g., BRAF, 
KRAS, HER2, KIT, ALK, NRAS, PDGFRA, PIK3CA, and MET). 
Therefore, at that time, carboplatin and pemetrexed were provided 
and because of pain, local irradiation of a sternal metastasis was 
applied. After two cycles of chemotherapy, the patient showed 
disease progression and was referred to our hospital. Because of 
lack of new treatment options, this patient was discussed in the 
Groningen MTB consisting of pulmonary oncologists, patholo-
gists, clinical molecular biologists in pathology, general oncolo-
gists, and a structural biologist (www.moloncopath.nl). The MTB 
advised to determine the HER2-copy number status as a possible 
resistant mechanism for EGFR TKI. Fluorescent in situ hybridiza-
tion (FISH) on a biopsy of a subcutaneous thoracic metastasis 
revealed HER2 amplification and treatment with afatinib (dual 
EGFR and HER2 inhibitor) 30 mg QD was started in October 
2015. Evaluation by 18-fluorodeoxyglucose positron emission 
tomography and computer tomography (18-FDG-PET-CT) 
showed after 6 weeks a significant partial response with disap-
pearance of the FDG activity of the bone metastases and after 
4 months in the left upper lobe a single FDG-positive lesion was 
left. This lesion was irradiated by means of stereotactic ablative 
radiotherapy (1× 20 Gy), and afatinib was continued. Treatment 
with afatinib was well tolerated with minor skin rash; patient 
showed clinical improvement: he had less pain and more energy. 
Nine months after start of afatinib, progressive disease was again 
noticed. Growth of the primary tumor in the left upper lobe, a 
new ipsilateral pulmonary lesion and multiple new bone metas-
tases including the skull, with ingrowth into the brain, causing 
paralysis of the right facial nerve (Figure 1). Sequence analysis 
of a new right-sided rib lesion showed the known L858R EGFR 
mutation and an additional T790M mutation.
Because of the novel T790M, afatinib was discontinued and 
replaced by osimertinib 80 mg QD (1). Eight weeks after start of 
osimertinib a PET-CT showed a response of most lesions except 
for a growing lesion in the pelvic region and the skull with 
ingrowth in the brain. Clinically there was, however, temporary 
improvement of the patient’s ability to move his right eyelid 
and right corner of the mouth, which had been paralyzed due 
to ingrowth of a skull metastasis into the brain and right facial 
nerve. A biopsy was performed of a growing FDG-positive 
lesion in the left pelvic bone that showed adenocarcinoma with 
the known L858R EGFR mutation, but the previously found 
T790M mutation was not present in this location (no biopsy 
of the skull metastasis available). The MTB advised to perform 
immunohistochemistry on Her2Neu (positive in agreement 
with HER2 amplification) and to determine MET amplification 
(negative by FISH). Based on these findings, it was decided 
to discontinue osimertinib because of the loss of the T790M 
mutation and to start a combination of paclitaxel 90 mg/m2 on 
days 1, 8, and 15, and trastuzumab 4 mg/kg on days 1 and 15, 
in cycles of 4 weeks, because trastuzumab is an HER2 antibody. 
Radiotherapy 1× 8 Gy was given on the pelvic lesion because of 
localized pain. 18-FDG-PET-scan after four cycles, paclitaxel 
and trastuzumab showed again a partial tumor response. No 
major side effects were observed although symptoms of the 
taBle 1 | Overview of clinical and pathological findings and subsequent therapeutic decisions.
Clinical evaluation Mutational status Ct/MRI evaluation therapy
Adenocarcinoma of the left lung with multiple bone metastases in 
sternum, ribs, and vertebrae
Femur: EGFR-L858R April 2015 Gefitinib
Progression of bone metastases (time to progression: 2 months) Rib: EGFR-L858R July 2015 Carboplatinum and pemetrexed
Irradiation on sternum
Progression of bone and subcutaneous metastases (time to 
progression: 2 months)
Thoracic subcutis: HER2 
amplification 3+
September 2015 Afatinib
Partial response with disappearance of the FDG activity of the bone 
metastases. Only 1 FDG-positive lesion in the left upper lobe
N.a. March 2016 Stereotactic ablative radiotherapy of 
lesion left upper lobe
Continuation of afatinib
Growth of primary tumor left upper lobe, ipsilateral pulmonary lesion, 
and multiple new bone metastases including the skull, with ingrowth 
into the brain (time to progression: 9 months)
Rib: EGFR-L858R and T790M July 2016 Osimertinib
Mixed response: growing lesion left pelvic bone Pelvic bone: EGFR-L858R, HER2 
amplification 3+, no T790M
October2016 Paclitaxel and trastuzumab
Irradiation on pelvic lesion
Subcutaneous metastasis on forehead and progression of bone 
metastases (time to progression: 6 months)
HER2 expression April 2017 Afatinib
Irradiation on cervical and thoracic 
vertebrae
N.a. Thorax wall: EGFR-L858R and 
T790M mutation and HER2 
amplification 3+
June 2017 Afatinib and osimertinib
Partial response N.a. November 2017 Continuation of afatinib and osimertinib
Progressive disease Thorax wall: EGFR-L858R, 
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paralysis of the right facial nerve did not improve further; it 
remained stable during the course of therapy. The patient 
underwent plastic surgery on his right eyelid, which improved 
the closure of his right eye.
Two months after the fourth and last cycle, the patient pre-
sented with a subcutaneous metastasis on his forehead. Afatinib 
30 mg QD was started, because this treatment worked before, 
pending results of a new biopsy. The biopsy, however, yielded 
insufficient material for mutation analysis, and re-biopsy was 
scheduled. In the meantime, 18-FDG-PET-scan showed multi-
ple FDG-positive bone lesions (partly new lesions), some close 
to the myelum, and the patient was admitted to the hospital 
for radiotherapy on cervical and thoracic vertebrae. Afatinib 
was discontinued. Biopsy of a new lesion in the thoracic wall 
showed an EGFR-L858R, T790M mutation, and HER2 amplifi-
cation. There were no other hotspot mutations in EGFR, BRAF, 
KRAS, ERBB2 (HER2), ALK, PIK3CA, or MET detected. The 
case was again reviewed by MTB. It was decided to treat the 
patient with afatinib 30  mg QD as well as osimertinib 80  mg 
QD at alternating days, to address the T790M mutation as well 
as the HER2 amplification resistance mechanism. Since the 
start of this latest treatment regimen, the subcutaneous skull 
metastasis disappeared, and the patient experienced less pain, 
regained his energy, and was able to walk outdoors again. The 
most recent 18-FDG-PET-CT-scan, 4 months after the start of 
this latest treatment regimen, showed again a partial response of 
the bone metastases again. Two months later (December 2017) 
progression of disease was observed, and the performance status 
deteriorated. Patient insisted to take a new biopsy from a new 
thoracic wall metastasis. Mutations analysis showed the known 
EGFR L858R and T790M mutations together with a new muta-
tion in HER2: L755S. However, his condition got worse in short 
time, and he died in January 2018. An overview of the clinical 
findings, the mutational status at different time points and the 
given treatment regimens is provided in Table 1.
BaCKGRoUND
eGFR
The incidence of EGFR mutations in advanced stage adenocar-
cinoma of the lung in Caucasian patients is 10–15 and 40–60% 
in Asian patients (2). In the north of the Netherlands, the inci-
dence is 9% (3). L858R mutation in exon 21 of the EGFR kinase 
domain is the main hotspot mutation in the EGFR gene and 
accounts for 35–45% of EGFR mutations (4, 5). L858R mutation 
increases the kinase activity of EGFR, leading to hyperactivation 
of downstream signaling pathways improving cell survival and 
proliferation (6). An EGFR TKI is the preferred first-line treat-
ment in patients with activating EGFR mutation in non-small-cell 
lung carcinoma (NSCLC) (4). Gefitinib and erlotinib are first-
generation TKI and registered as first-line treatment in patients 
with metastatic NSCLC with a tumor harboring an activating 
EGFR mutation within the European Union and according to 
the Dutch guideline for treatment of NSCLC (7). These small 
molecules bind competitively and reversibly to the adenosine 
triphosphate (ATP) binding site of the tyrosine kinase domain of 
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EGFR. This prevents the autophosphorylation of the TK, blocks 
the activation of the EGFR signal transduction, inhibits tumor 
cell proliferation, and induces cell cycle arrest and apoptosis 
(8). The majority of patients will progress after 9–12 months of 
treatment due to various mechanisms of intrinsic or acquired 
resistance to first-generation EGFR TKIs (9).
eGFR t790M
The most common mechanism of acquired TKI resistance is 
the acquisition of a single recurrent missense mutation within 
exon 20, the T790M mutation (10). This mutation leads to the 
substitution of threonine by methionine at position 790, which 
encodes part of the kinase domain of the receptor and results 
in increased affinity for ATP (11). The T790M mutation can 
be detected in about 60% of tissue biopsy samples taken after 
acquired resistance (12, 13). As residue threonine at position 
790 (T790) is located at the entrance in the back of the ATP 
binding cleft, substitution of residue threonine at position 790 
with a bulky methionine (resulting in T790M) may cause steric 
interference with binding of TKIs (14). Irreversible inhibitors 
overcome this resistance simply through covalent binding (15). 
Osimertinib is registered for the treatment of NSCLC with 
an EGFR T790M mutation. It is a selective third-generation 
TKI which targets the ATP binding site of EGFR via irrevers-
ible covalent bond formation. In contrast to many other TKI, 
osimertinib penetrates the blood–brain barrier (16, 17). 
Osimertinib improves overall survival and progression-free 
survival in T790M-positive NSCLC patients with and without 
brain metastases (18, 19). Acquired resistance to osimertinib 
may be caused by primary coexistence of tumor cell popula-
tions with and without T790M mutation due to EGFR C797S 
mutation. Tumor progression can be explained by growth of the 
T790M negative population, while the tumor cells expressing 
T790M mutation are effectively suppressed by osimertinib (20).
HeR2
Overexpression of HER2 induces cell transformation and 
tumorigenic growth and is clinically associated with resistance 
to erlotinib (21). HER2 amplification is detected in a subset 
of EGFR TKI resistant lung tumors. HER2 amplification and 
T790M mutation are thought to be mutually exclusive (22). 
However, in our patient HER2 amplification as well as T790M 
mutation appeared in the same biopsy of a new lesion in the 
thorax wall. Afatinib is an ATP-competitive aniline-quinazoline 
derivate which covalently binds to EGFR, HER2, and HER4 and 
irreversibly inhibits HER-family phosphorylation and signal 
transduction (23). As second generation TKI it is highly potent, 
irreversible dual EGFR/HER2 tyrosine kinase inhibitor, includ-
ing the oncogenic EGFR-L858R mutation (23, 24). Afatinib is 
registered for advanced NSCLC with EGFR mutations. Clinical 
benefit of afatinib seems less in patients with de novo T790M 
mutations (25). Although afatinib is equally potent against 
wild-type EGFR and EGFR harboring the T790M mutation, in 
patients the dose is lower due to toxicity constraints (26).
Trastuzumab, a humanized monoclonal antibody against 
HER2, has been reported to be effective in HER2-positive NSCLC 
in vitro and in case reports (4, 27, 28).
DIsCUssIoN
Here, we describe a patient with EGFR mutant advanced NSCLC 
with recurrent episodes of disease progression due to subsequent 
mutant clones. Yu et al. selected 155 patients with lung adenocar-
cinomas and acquired resistance to erlotinib or gefitinib. These 
patients underwent a re-biopsy. The most common finding was 
a T790M mutation. They also found transformation to small cell 
lung carcinoma, MET amplification and HER2 amplification 
(10). Sequist et al. described a wide variety of gained and lost 
EGFR mutations in a patient population with acquired drug 
resistance. They recommended reassessing cancers by taking 
new biopsies of growing lesions in patients with progressive 
disease after an initial response to TKI treatment (29). Following 
this strategy, we observed HER2 amplification and T790M 
mutation at different time points under the selective pressure of 
different EGFR TKI treatment. Of note, the occurrence of both 
aberrations at the same time has not been described earlier.
After discussion in the MTB about the most suitable therapy, 
as mentioned in the background, treatment was adjusted accord-
ingly. Case evaluation by a multidisciplinary MTB is important 
to benefit from individualized genetic data and maximize clinical 
impact (30–32). MTB interprets results of routine molecular 
NGS-testing with those of other techniques, for example, 
immunohistochemistry, FISH, DNA methylation testing, and 
multiplex ligation-dependent probe amplification. NGS testing 
is not only performed on biopsies but currently also from tumor 
DNA in peripheral blood. The spectrum of molecular markers 
is constantly growing. Patients who progress after an EGFR 
TKI should undergo a re-biopsy to perform molecular analysis 
specifically looking for acquired mechanisms of resistance, such 
as EGFR T790M mutation. This approach can influence the 
next therapeutic step or reveal alternative EGFR TKI resistance 
mechanisms such as transformation to small cell lung cancer or 
bypass tracks that could potentially be addressed in clinical trials 
(11). Our patient responded well to subsequent treatment based 
on aberrations found in NGS, IHC, and FISH after discussion 
in the MTB. We observed that a change in treatment gave a 
short-lasting clinical improvement of several months and tumor 
response of fast growing new metastases. Osimertinib alternating 
with afatinib for T790M in EGFR and HER2 amplification was 
very effective in decreasing tumor sites. However, we expected 
that our patient would have immense toxicity of skin rash and 
diarrhea, but toxicity was not more than CTC grade 1. Long-
lasting tiredness grade 1 was the most prominent side effect.
CoNClUDING ReMaRKs
This case report shows the importance of re-biopsy of growing 
lesions in lung cancer patients with metastatic progressive disease 
under targeted therapies. Mutation status can vary under selection 
pressure of these drugs, and knowledge of these changes makes 
it possible to adapt treatments. This patient also exemplifies the 
importance of having a multidisciplinary expert team (MTB) to 
give rational treatment advice in cancer patients with uncommon 
mutations or combinations of mutations causing complex resist-
ance mechanisms.
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